financetom
Business
financetom
/
Business
/
US FDA declines to approve AbbVie's Parkinson's disease therapy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA declines to approve AbbVie's Parkinson's disease therapy
Jun 25, 2024 5:40 AM

June 25 (Reuters) - AbbVie ( ABBV ) said on Tuesday the

U.S. Food and Drug Administration has rejected the company's

marketing application for its therapy to treat motor

fluctuations in adults with advanced Parkinson's disease.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bayer must pay $78 mln in latest Roundup cancer trial, jury finds
Bayer must pay $78 mln in latest Roundup cancer trial, jury finds
Oct 10, 2024
Oct 10 (Reuters) - Bayer must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday. The verdict in state court in Philadelphia follows previous consecutive victories for Bayer in that court. The company has won 14 of the previous 20 trials over...
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Oct 10, 2024
Oct 10 (Reuters) - Drug developer Denali Therapeutics ( DNLI ) said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals. ...
Looking At American Express's Recent Unusual Options Activity
Looking At American Express's Recent Unusual Options Activity
Oct 10, 2024
High-rolling investors have positioned themselves bearish on American Express ( AXP ) , and it's important for retail traders to take note. This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AXP often signals that someone has privileged information. Today, Benzinga's...
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
Oct 10, 2024
WASHINGTON, Oct 10 (Reuters) - New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday. Kickbacks designed to induce referrals or purchases of healthcare goods or services distort physician and patient decision-making, thwart competition and bypass...
Copyright 2023-2026 - www.financetom.com All Rights Reserved